

RECEIVED
CENTRAL FAX CENTER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAR 13 2006

In the Application of:)	Examiner: Padmashri Ponnaluri
TSAI, David)	Art Unit: 1639
<i>10/772,537</i>)	
Serial No. <u>11/315,810</u>)	Attorney Docket No.: 04-01-2174
Filed: 12/22/2005)	
Title: A method for treating obesity)	
with Zinc-charged polypeptides)	

Certificate of Transmission (37 CFR 1.8):

I hereby certify that this correspondence is being transmitted to the United States Patent and Trademark Office by facsimile (571) 273-8300 (ten pages) on March 13, 2006.



By: _____

R. Joseph Trejan
Reg. No. 34,264

AMENDMENT AND RESPONSE
TO FINAL OFFICE ACTION DATED 02/02/2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TELEPHONE INTERVIEW SUMMARY

Dear Sir or Madam:

On February 27, 2006 at 11:50 PST the Applicant initiated a telephone interview regarding this application with Examiner Padmashri Ponnaluri. Per Examiner's request, the Applicant hereby memorializes the content of the interview.

An agreement has been reached between the Examiner and the Applicant regarding the amendments to the single pending claim that would place the application in condition for allowance. Specifically, the Examiner recommended and the Applicant agreed to amend the single pending claim (Claim 15) as follows:

"A fetuin polypeptide comprising an consisting of the amino acid sequence of His-Ser-Phe-Ser-Gly-Val-Ala-Ser-Val-Glu SEQ. ID NO: 4,

Application Number 10/772,537

Art Unit 1639

wherein said polypeptide causes apoptosis in colon and prostate cancer cells”

The examiner also noted that such a use of sequence identifier would address the Claim Objections of the February 2, 2006 Office Action.